Christopher Mantle, MD
Otolaryngology · Nashville, TNNPI 1104973924
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $443, more than ten times the $17 reported in 2019. That places this record below the midpoint for otolaryngology clinicians in TN, where the typical reported total is $1,839.
Across 44 payments — averaging $25.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$261
- Optinose US, Inc.$240
- Sanofi$156
- Stryker$108
- AbbVie$59
- Alk-abello, Inc$51
- plus $234 from 11 others
What the payments were for
- Food & beverage$1,111100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 9 | $261 |
| Optinose US, Inc. | 10 | $240 |
| Sanofi | 6 | $156 |
| Stryker | 5 | $108 |
| AbbVie | 1 | $59 |
| Alk-abello, Inc | 2 | $51 |
| Merck | 1 | $31 |
| Integra Lifesciences Corporation | 1 | $27 |
| Neurent Medical Limited | 1 | $25 |
| Genentech USA, Inc. | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $17 |
| Olympus America Inc. | 1 | $17 |
| GSK | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
How this compares
$1,111 in reported general payments places this provider in the 35th percentile of 191 otolaryngology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mometasone Furoate | 143 | $13,006 |
| Fluticasone Propionate | 258 | $4,752 |
| Ipratropium Bromide | 110 | $4,035 |
| Montelukast Sodium | 318 | $3,753 |
| Olopatadine Hcl | 29 | $2,418 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 20 | $2,249 |
| Cefdinir | 66 | $1,557 |
| Ofloxacin | 34 | $1,371 |
| Azelastine Hcl | 60 | $1,277 |
| Famotidine | 113 | $1,139 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 54 | $825 |
| Esomeprazole Magnesium | 18 | $813 |
| Doxycycline Hyclate | 49 | $583 |
| Methylprednisolone | 82 | $481 |
| Levocetirizine Dihydrochloride | 28 | $437 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Nashville
- Rakesh ChandraNashville$381K
- Michael TopfNashville$36K
- Naweed ChowdhuryNashville$14K
- Steven EnrichNashville$11K
- Kareem TawfikNashville$10K
- Mark WilliamsNashville$8K
- Matthew SpeyerNashville$6K
- David KentNashville$4K
- Kyle MannionNashville$4K
- Charles BabbNashville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.